ELVN Enliven Therapeutics
- 20.470
- -1.090-5.06%
- 20.470
- 0.0000.00%
Enliven Therapeutics News
Enliven Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/11/2024 40.41% Baird → $32 Initiates Coverage On → Outperform 04/09/2024 49.19% Mizuho → $34 Initiates
Express News | Enliven Therapeutics Inc : Baird Initiates Coverage With Outperform Rating; Target Price $32
Enliven Therapeutics(ELVN.US) Officer Sells US$22,722.43 in Common Stock
$Enliven Therapeutics(ELVN.US)$ Officer Patel Anish sold 1,133 shares of common stock on Jun 6, 2024 at an average price of $20.0551 for a total value of $22,722.43.Source: Announcement What is statem
Baird Initiates Enliven Therapeutics(ELVN.US) With Buy Rating, Announces Target Price $32
Baird analyst Colleen M. Kusy initiates coverage on $Enliven Therapeutics(ELVN.US)$ with a buy rating, and sets the target price at $32.According to TipRanks data, the analyst has a success rate of 30
LifeSci Capital Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Maintains Target Price $38
LifeSci Capital analyst Sam Slutsky maintains $Enliven Therapeutics(ELVN.US)$ with a buy rating, and maintains the target price at $38.According to TipRanks data, the analyst has a success rate of 47.
Enliven Therapeutics(ELVN.US) Officer Sells US$260.8K in Common Stock
$Enliven Therapeutics(ELVN.US)$ Officer Lyssikatos Joseph P sold 12,000 shares of common stock on May 29, 2024 at an average price of $21.7333 for a total value of $260.8K.Source: Announcement What is
Enliven Therapeutics(ELVN.US) Officer Sells US$98,530.29 in Common Stock
$Enliven Therapeutics(ELVN.US)$ Officer Hohl Benjamin sold 4,250 shares of common stock on May 28, 2024 at an average price of $23.1836 for a total value of $98,530.29.Source: Announcement What is sta
Enliven Therapeutics(ELVN.US) Officer Sells US$278.21K in Common Stock
$Enliven Therapeutics(ELVN.US)$ Officer Kintz Samuel sold 12,000 shares of common stock on May 28, 2024 at an average price of $23.1842 for a total value of $278.21K.Source: Announcement What is state
Enliven Therapeutics to Present at Two Upcoming Investor Conferences
BOULDER, Colo., May 29, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven) (NASDAQ:ELVN), a clinical-stage precision oncology company focused on the discovery and development of next-generation small
Strong Buy Rating for Enliven Therapeutics' ELVN-001 Amid Favorable Market Dynamics
Enliven Therapeutics(ELVN.US) Director Sells US$30,149.67 in Common Stock
$Enliven Therapeutics(ELVN.US)$ Director Heyman Richard A. sold 1,270 shares of common stock on May 16, 2024 at an average price of $23.7399 for a total value of $30,149.67.Source: Announcement What i
Enliven Therapeutics Insider Sold Shares Worth $22,877,262, According to a Recent SEC Filing
Rishi Gupta, 10% Owner, Director, on May 16, 2024, sold 1,033,300 shares in Enliven Therapeutics (ELVN) for $22,877,262. Following the Form 4 filing with the SEC, Gupta has control over a total of 7,6
Form 144 | Enliven Therapeutics(ELVN.US) Director Proposes to Sell 121.77K in Common Stocks
SEC FILLINGS DISCLOSED/ May 17, $Enliven Therapeutics(ELVN.US)$ Director The Biotech Growth Trust PLC intends to sell 5,500 shares of its common stock on May 16, with a total market value of approxima
Form 144 | Enliven Therapeutics(ELVN.US) Director Proposes to Sell 22.14 Million in Common Stocks
SEC FILLINGS DISCLOSED/ May 17, $Enliven Therapeutics(ELVN.US)$ Director OrbiMed Private Investments VII, LP intends to sell 1 million shares of its common stock on May 16, with a total market value o
Form 144 | Enliven Therapeutics(ELVN.US) Director Proposes to Sell 737.26K in Common Stocks
SEC FILLINGS DISCLOSED/ May 17, $Enliven Therapeutics(ELVN.US)$ Director OrbiMed Genesis Master Fund, L.P. intends to sell 33,300 shares of its common stock on May 16, with a total market value of app
Enliven Therapeutics(ELVN.US) Officer Sells US$27,675 in Common Stock
$Enliven Therapeutics(ELVN.US)$ Officer Patel Anish sold 1,107 shares of common stock on May 14, 2024 at an average price of $25 for a total value of $27,675.Source: Announcement What is statement of
Enliven Therapeutics: A Strong Buy on Market Dynamics and Scemblix's Breakthrough Therapy Designation Impact
Analysts Offer Insights on Healthcare Companies: Iridex (IRIX), Nyxoah (NYXH) and Enliven Therapeutics (ELVN)
Enliven Therapeutics GAAP EPS of -$0.54 Beats by $0.02
TD Cowen Sticks to Their Buy Rating for Enliven Therapeutics (ELVN)
Analysis
Price Target
No Data
